• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

WHY IS EIASI'S BOARD SO NEGATIVE???

Naito is a below average CEO at best. The only meaningful thing he has done in the last 20 years was to make the move to enter the US when almost all other Japanese companies wanted nothing to do with North America. That was more balls than smarts though. Since then, it's been one horrible decision after another.

He was here to pick the low hanging fruit, now it's onto other markets where he can unload the old merchandise, grab a few more yen, then it will be time to retire and who cares after that?